{"entity":{"id":"nct07222488","kind":"trial","name":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","aka":[],"tldr":"A phase 1/2 trial of MK-3120 in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) is a phase 1/2 interventional study registered as NCT07222488 by Merck Sharp & Dohme LLC, with 45 participants planned, started 2025-12-09 and due to reach its primary completion in 2029-02-28. Interventions recorded: MK-3120.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07222488","url":"https://clinicaltrials.gov/study/NCT07222488"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","non-muscle-invasive-bladder-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07222488","phase":"1/2","setting":"Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer","sponsor":"Merck Sharp & Dohme LLC","started":"2025-12-09","startedType":"actual","enrolled":45,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07222488/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}